The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia

Toll interleukin-1 receptor 8 (also known as TIR8, SIGIRR, or IL1R8) is a transmembrane receptor that inhibits inflammation. Accordingly, genetic inactivation of this protein exacerbates chronic inflammation and inflammation-associated tumors in mice. In particular, lack of TIR8 triggers leukemia pr...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2017-10, Vol.58 (10), p.2419-2425
Main Authors: Vilia, Maria Giovanna, Fonte, Eleonora, Veliz Rodriguez, Tania, Tocchetti, Marta, Ranghetti, Pamela, Scarfò, Lydia, Papakonstantinou, Nikos, Ntoufa, Stavroula, Stamatopoulos, Kostas, Ghia, Paolo, Muzio, Marta
Format: Article
Language:English
Subjects:
Azacytidine
chronic lymphocytic leukemia
Medicin och hälsovetenskap
SIGIRR
TIR8
toll interleukin-1 receptor 8
Toll like receptors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Toll interleukin-1 receptor 8 (also known as TIR8, SIGIRR, or IL1R8) is a transmembrane receptor that inhibits inflammation. Accordingly, genetic inactivation of this protein exacerbates chronic inflammation and inflammation-associated tumors in mice. In particular, lack of TIR8 triggers leukemia progression in a mouse model of chronic lymphocytic leukemia (CLL), supporting its role as a novel tumor restrainer. The aim of this study was to measure the amount of TIR8 mRNA and protein in CLL cells, and to analyze its regulation of expression. Circulating leukemic cells expressed lower levels of TIR8 compared to normal B-lymphocytes. Treatment of CLL cells with Azacytidine restored higher levels of TIR8 suggesting that DNA methylation may be involved in modulating TIR8 expression, with implications for novel therapeutic strategies.
ISSN:1042-8194
1029-2403
1029-2403
DOI:10.1080/10428194.2017.1295142